Codexis (NASDAQ:CDXS) Posts Quarterly Earnings Results, Misses Estimates By $0.09 EPS

Codexis (NASDAQ:CDXS - Get Free Report) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.09), Zacks reports. Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. The company had revenue of $21.46 million for the quarter, compared to analysts' expectations of $27.41 million. Codexis updated its FY 2025 guidance to EPS.

Codexis Stock Down 9.9 %

Shares of CDXS traded down $0.30 during mid-day trading on Monday, hitting $2.74. 2,060,974 shares of the company traded hands, compared to its average volume of 561,489. The business has a 50 day moving average of $4.56 and a 200 day moving average of $3.97. The company has a market capitalization of $222.98 million, a PE ratio of -3.15 and a beta of 2.12. The company has a quick ratio of 3.15, a current ratio of 3.21 and a debt-to-equity ratio of 0.39. Codexis has a 1-year low of $2.56 and a 1-year high of $6.08.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Benchmark restated a "hold" rating on shares of Codexis in a report on Monday, November 4th. Cantor Fitzgerald reissued an "overweight" rating and issued a $11.00 target price on shares of Codexis in a report on Friday, November 22nd.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.